AR120165A1 - OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF - Google Patents
OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOFInfo
- Publication number
- AR120165A1 AR120165A1 ARP200102766A ARP200102766A AR120165A1 AR 120165 A1 AR120165 A1 AR 120165A1 AR P200102766 A ARP200102766 A AR P200102766A AR P200102766 A ARP200102766 A AR P200102766A AR 120165 A1 AR120165 A1 AR 120165A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- oligonucleotide compositions
- present disclosure
- disclosure provides
- c9orf72
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000043334 C9orf72 Human genes 0.000 abstract 2
- 108700030955 C9orf72 Proteins 0.000 abstract 2
- 101150014718 C9orf72 gene Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Entre otras cosas, la presente divulgación proporciona oligonucleótidos de C9orf72, composiciones y métodos de los mismos. En algunas realizaciones, la presente divulgación proporciona métodos para tratar afecciones, trastornos o enfermedades asociados con C9orf72, tales como escleorosis lateral amiotrófica y demencia frontotemporal.Among other things, the present disclosure provides C9orf72 oligonucleotides, compositions, and methods thereof. In some embodiments, the present disclosure provides methods for treating conditions, disorders, or diseases associated with C9orf72, such as amyotrophic lateral sclerosis and frontotemporal dementia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962911340P | 2019-10-06 | 2019-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR120165A1 true AR120165A1 (en) | 2022-02-02 |
Family
ID=80782157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102766A AR120165A1 (en) | 2019-10-06 | 2020-10-06 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR120165A1 (en) |
-
2020
- 2020-10-06 AR ARP200102766A patent/AR120165A1/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022004102A (en) | COMPOSITIONS OF OLIGONUCLEOTIDES AND METHODS OF USE THEREOF. | |
| WO2020227691A3 (en) | Oligonucleotide compositions and methods of use thereof | |
| MX2022004101A (en) | COMPOSITIONS OF OLIGONUCLEOTIDES AND METHODS OF USE THEREOF. | |
| NI201900085A (en) | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | |
| CL2018001089A1 (en) | Valbenazine salts and polymorphs thereof. | |
| MX2021009178A (en) | COMPOSITIONS OF OLIGONUCLEOTIDES AND METHODS THEREOF. | |
| MX2019002750A (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer. | |
| MX379543B (en) | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS 1. | |
| MX2020010999A (en) | MODULATORS OF METHYL MODIFIING ENZYMES, COMPOSITIONS AND THEIR USES. | |
| DOP2016000295A (en) | COMPOUNDS AND COMPOSITIONS AS AGENTS OF THE TOLL TYPE 7 RECEIVER | |
| WO2016029191A3 (en) | Channel modulators | |
| MX2024000349A (en) | Compounds and uses thereof. | |
| MX2016014308A (en) | COMPOUNDS AND COMPOSITIONS AS AGENTS OF THE TOLL TYPE RECEIVER 7. | |
| UY34654A (en) | BETA-SECRETASA INHIBITORS | |
| UY35628A (en) | ? HETEROAROMATIC COMPOUNDS AND ITS USE AS DOPAMINE DIGINAL LINKS ?. | |
| MX2014008773A (en) | COMPOSITIONS AND METHODS FOR THE USE OF FORBOL ESTERS. | |
| BR112017007063A2 (en) | compositions and methods for treating insomnia | |
| CO2019002889A2 (en) | Combination treatments comprising the administration of imidazopyrazinones | |
| BR112017012504A2 (en) | piperidine derivatives as hdac1 / 2 inhibitors | |
| ECSP17081322A (en) | MUSCARINIC RECEIVER M2 POSITIVE ALLOSTERIC MODULATORS | |
| DOP2021000251A (en) | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | |
| MX2024006769A (en) | Compounds and uses thereof. | |
| MX2020011826A (en) | COMBINATION COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THEREOF. | |
| CL2019001091A1 (en) | Combination treatments that include the administration of imidazopyrazinones. | |
| PH12016501159A1 (en) | Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |